The human T-cell lymphotropic virus type I (HTLV-I) was discovered in 1980. It is the first oncogenic human retrovirus [29] .
Introduction
The finding of ATL was established on clinical features, hypercalcemia, hematological findings, increased LDH value, detection of HTLV-I antibodies and immunophenotyping analyses. Four subtypes were used to classify the patients according to the classical criteria established by Shimoyama et al [39] .
Morphology and immunophenotyping
Bone-marrow aspirate and/or peripheral-blood were examined in all cases according to Catovsky et al (1984) . Immunophenotyping analyses were performed routinely using a clean peripheral blood mononuclear cell (PBMC) from the patients, by flow cytometry using a panel of fluorochrome-conjugated monoclonal antibodies including, CD2, CD3, CD4, CD7, CD8, CD25, CD30, CD38, HLADr, CD19 and CD45RO, for a four-color fluorescent analysis on a FACS facscalibur flow cytometer (BD Biosciences). For patients having leukemic signs, the criteria of T-cell type was accepted when above 25% of the circulating malignant cells were positive for T-cell markers [5, 32] .
HTLV-I serological assays
Collected from the patients, the peripheral blood samples were checked for the occurrence of antibodies to HTLV-I and II by the help of the enzyme immunoassay (ELISA -Vironostika HTLV-I/II Organon Teknika, Boxtel, Holland), in accordance with the manufacturer's directions. Repeatedly reactive on ELISA specimens were further given to a Western Blot assay (HTLV BLOT 2.4 Genelabs Diagnostics Pte. Ltd., Singapore) for verification and type differentiation in accordance with manufacturer's guidelines. This examination classifies as HTLV-positivity with the sample reactive to, no less than, two distinctive HTLV structural gene products: env gD21 and/or gp46 and gag p24 and/or p19; viral type was described as HTLV-I or HTLV-II when reactive to recombinant gp46-I or gp46-II, respectively; as HTLV-indeterminate in case of the pattern not meeting the positivity criteria, and as negative in case of total reactivity absence.
HTLV-I molecular assays
Using the ficoll-hypaque density gradient centrifugation, peripheral blood mononuclear cells (PBMC) were separated, and extraction of DNA was done from PBMC using the QIAamp DNA Blood Mini Kit -Qiagen (Hilden Germany), in accordance with manufacturer's guidelines. Finding of HTLV-I sequences was carried out by PCR making use of specific primers for three distinguished HTLV genomic regions (LTR, tax, pol) as explained elsewhere [7, 36] .
Statistical analysis
The 2 test was used to compare race and gender proportion in the analyzed group with a p-value of 0.05. Survival rates for each patient were calculated from diagnosis confirmation until death or censure.
Data were analyzed with the use of the Kaplan-Meier Curve, and
Comparisons among ATL subgroups were carried out using logrank test (significance p-value 0.05). Every statistical test was done using the Statistical Package for the Social Sciences (SPSS) v.13.0 software (SPSS Inc, Chicago, II, USA).
Results

Clinical features
Forty-six patients with T-cell disease HTLV-I positive were diagnosed between January 1995 and December 2007. ATL was confirmed in 37 patients enrolled in this study. Among the ATL cases, 22 (59%) presented acute subtype, eight (22%) chronic subtype, seven (19%) lymphoma type and no cases of smoldering subtype were found.
During evolution, nineteen of the patients with chronic or lymphoma type changed to acute subtype (Tab. I and II).
The main characteristics of the 37 ATL patients are summed up in table I, and II. The span of time between the showing of the symptoms and the diagnosis varied from eight days to five years (just the case 15). Generalized lymphoadenopathy, hepatomegaly, splenomegaly, skin lesions and hypercalcaemia were features present in many patients (Tab. II). Two of them had osteolytic lesions. There were two cases of pulmonary infiltrate (Fig. 1, case 15 ) and ten cases (27%) had central-nervous system involvement. One patient had ATL concomitant with Hansen's disease (Fig. 2 , case one). Case eight illustrates the typical ATL skin lesion (Fig. 3) .
Although HAM/TSP and ATL are distinguished clinical entities caused due to HTLV-I, there was one case of ATL concomitantly with HAM/ TSP. This patient suffered from sphincter dysfunction, gate difficulty, and spastic paraparesis of the lower limbs, brisk reflexes and hyperreflexia with HTLV-I antibodies found in the CSF. Each and every of these clinical symptom fulfilled the diagnostic criteria of HAM/TSP [18] . These signs began one year before ATL symptoms.
Laboratory features
The results of laboratory findings and risk factors were described in table I and II. Eighteen cases (49%) had an increased LDH levels; hypercalcaemia was present in 20 patients (54%). The range of white-blood-cell (WBC) counts goes from 2,090 to 425,000 k/µl.
Cell morphology seems to be of nucleus shape and pleomorphic in size. Flower cells were found in twenty-three patients (62%) peripheral blood. In most cases, the Immunophenotyping by flow cytometry was positive for CD2, CD3, CD4, CD5, CD25, HLADr and CD45 and negative for CD7, CD8 and CD19, a typical T-cell phenotype. Co-expression of positive CD4 and CD8 was found in one case and in three patients the CD4 and CD8 were negative. In particular CD25 was negative in four cases. All cases had antibodies to HTLV-I confirmed by Western Blot; PCR was performed in 22 cases and the HTLV-I viral segment was detected in all of them. 
Survival analysis
Survival data were compared between the subtypes of ATL using the log-rank test and Kaplan-Meier to evaluate statistical significance.
The period starting from the date of diagnosis till the moment of death or censure was defined as the survival time. Cases with missing follow-up or which completed the follow-up period were censored alive at that time. Although one of the cases had exceeded the following five years (almost 7 years), the data were censored on the 60th month of observation.
Analyzing the curves, overall survival data were relatively short (median 2.0 months, 95% between 0 and 5.6 months). However, those with chronic disease had longer survival (median 15.0 months, 95% between 0 and 37.6 months). The lymphoma subtype group had the worst prognosis (median survival 1.0 month). Given the small number of cases, it was not possible to detect a statistically significant difference between groups (log-rank test 0.74). The major reason for death was advancement of the disease linked with hypercalcemia and infective complications (Fig. 4) . Table describes clinical evolution.
Epidemiology
The age of ATL patient was found between 23 to 91 years, with an average of 42 years. There were 11 males (30%) and 26 females (70%), with significant differences regarding gender in the total group analyzed (p = 0.014). Twenty five (67.6%) patients were non-white ATL-a -adult T-cell leukemia/lymphoma acute; ATL-c -adult T-cell leukemia/lymphoma chronic ; ATL-l -adult T-cell leukemia/lymphoma lymphoma ATL-ca -adult T-cell leukemia/lymphoma chronic evoluted to acute-subtype; ATL-la -adult T-cell leukemia/lymphoma lymphoma evoluted to acute-subtype; nd = not done; M -Male; F -Female; W -white; NW -non white; BD HTLV-I + -blood donor HTLV-I +; HAM/TSP -HTLV-I-associated myelopathy/tropical spastic paraparesis; HIV -human immunodeficiency virus; HPV -human papilloma virus; HBV -hepatitis B virus; HCV -hepatitis C virus; * -not smoldering cases were found.
compared to twelve (32.4%) white. There were significant differences regarding ethnicity in the total group analyzed (p = 0.033).
According to the regional origin, the patients were from five different states of Brazil: thirty were from Rio de Janeiro, four from Bahia, one from Pernambuco, one from Maranhão and one from Pará.
Among the entire group, three of the patients were blood donor in others Brazilian studies [3, 32] . Co-expression of positive CD4
and CD8 was found in one case and in three patients the CD4 and CD8 were negative. In particular CD25 was negative in four cases.
These rare immunophenotypic variants were previously reported [32] . Hypercalcaemia was present in 54% of the cases, two patients presented osteolytic lesions and 37% of the patients presented CNS involvement. One patient, besides neurological disease had disseminated osteolytic lesions and Hansen's disease, as previously reported [14, 15, 25] .
In accordance with the disease presentation form, our results are similar to the data reported by Schimoyoma [39] where the frequency of ATL subtypes presents acute form 57%, lymphomatosis 19%, chronic 19% and smoldering 5%, except in smoldering form, where no case was found. there is a lack of durability in responses [13] .
ATL being a major destructive hematological malignancy has a bad outcome, either it is acute or lymphoma type, with a survival time of 6 to 13 months [47] . According to Lymphoma Study Groups [22] , the patient's survival rates were 24.3 month for the chronic type, 10.2 months for the lymphoma type and 6.2 months for the acute form, from a group of 854 individual patients. In a Brazilian study, in which 70 ATL cases were analyzed, the overall median survival time was 12 months [3] . Yet, we lay serious emphasis on the fact that in our study, lymphoma subtype group had the worst prognosis (median likely to be at a higher risk of getting the disease [1, 28] . It has been reported that the Brazilian patients are younger than the Japanese ones. In this study the average age was 42 years old, and it is similar to other regions of Brazil and from the Caribbean patients [3, 12, 32] .
Though mostly ATL is accounted to affect patients in their fifties, in Japan [42] , in the Jamaican and Brazilian series, the individuals are more likely to show the medical symptoms in the forth decade of their life [3, 4, 12, 32] .
Amongst the HTLV-I-infected carriers the cumulative incidence of ATL, is approximated at 1-5% for both males and females in endemic areas [26] . In our series, 26 (70%) of the patients were female. Similar results were found in a survey conducted in central Brooklyn, which showed the yearly incidence of ATL was higher in females as compared to males (female-to-male ratio of 3:1) [21] , however the disease is more common amongst men in Japan. Amongst the HTLV-I carriers in Japan, the cumulative incidence of ATL is approximated at 2.5%, with 1-2% in female and 3-5% in males [46] .
In French Guiana, a greater incidence of ATL in blacks has been accounted [10] as well as in blacks with mulattos in Pernambuco and Bahia States in Brazil [3, 32] . In the present study the disease was also majorly found in non-white individuals (68%).
In case of adult HTLV-I infection, the development of ATL is highly unusual and merely periodic cases of sexual transmission and/or blood transfusion related HTLV-I transmission related with ATL have been found [6, 23, 24] .
Although in our series four patients have history of blood transfusion before the diagnosis, it was not clearly the route of HTLV-I transmission.
In spite of the fact that HTLV-I infection caused by blood transfusion is regarded as a significant danger for HAM/TSP, instances of posttransfusion ATL are extraordinary [1, 6, 33] . ATL and HAM/TSP are distinguished clinical conditions triggered by HTLV-I, and one or the other disease shows up independently in most patients. Although, few cases of connection are reported [3, 16, 19, 32] . In our study just one patient was found with this disease association.
The incidence of HTLV-I, reported annually, of related disease (ATL)
has not been found in Brazil [32] . In addition, there are very few data available about the path of HTLV-I transmission among family settings of individuals with ATL in the region. Carvalho et al. [4] and Pombo-de-Oliveira [33] , found a HTLV-I seroprevalence rate of 27, 5% and 36% respectively amongst the family members of individuals with ATL and in the present study 35, 8% of the relatives of ATL patients analyzed were HTLV-I seropositive.
According to the risk factors, in our study 12 patients were breastfed by their mothers and among them 60% were HTLV-I positive and wet nurses breast fed four patients and their mothers were HTLV-I negative. These are in accordance with data found in Caribbean and Japanese cohort studies, where greater than 97%
of mothers of ATL individuals were as well HTLV-I antibody-positive [1, 40] .
In conclusion, our data emphasize the importance of the serologic test for HTLV-I antibodies, and specific immunophenotyping to differentiate ATL from other T-lymphoproliferative disorders. Alternatively, since ATL is majorly linked with HTLV-I infection in early years of life, transmitted by vertical route, it is very important to include in the prenatal routine the HTLV screening test and present the appropriate counseling to the seropositive pregnant women regarding to the breast-feeding, in order to brake the virus transmission cycle.
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